Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CASR | P41180 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4784822 | 0.86 | MEN1 (0.45) | KDM4EALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4737515 | 0.85 | CASR (0.45) | KDM4EALDH1A1GAACASRKMT2A | |
| SCHEMBL4737051 | 0.83 | BCL2 (0.55) | KDM4EALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL4736982 | 0.82 | KMT2A (0.52) | KDM4ECASRKMT2AMEN1MAPT | |
| SCHEMBL4741826 | 0.80 | CCR2 (0.43) | KDM4EALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3521617 | 0.79 | ALDH1A1 (0.51) | KDM4EALDH1A1CASRKMT2AMEN1 | |
| SCHEMBL4740478 | 0.78 | EGLN3 (0.45) | KDM4EALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL4739135 | 0.77 | ALDH1A1 (0.52) | KDM4EALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL4738470 | 0.77 | LMNA (0.51) | KDM4EALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL4737518 | 0.77 | EGLN3 (0.51) | ALDH1A1GAAKMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089051-A1 | N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | KDM4E 746/4885ALDH1A1 513/4885GAA 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.